Dempze Nancy E Increases Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Dempze Nancy E increased its stake in Eli Lilly and Company by 16.3% during the 2nd quarter, purchasing an additional 387 shares, bringing its total holdings to 2,761 shares valued at approximately $2.15 million.
• Analysts have expressed mixed sentiments on Eli Lilly's stock, with Daiwa Capital Markets downgrading it to "neutral" while Guggenheim raised its price target significantly from $875 to **$948**, maintaining a "buy" rating.
• Eli Lilly reported a significant quarterly performance with earnings per share of $6.31, exceeding estimates, and revenue of $15.56 billion, which is a year-over-year increase of 37.6%.

Dempze Nancy E boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,761 shares of the company's stock after purchasing an additional 387 shares during the period. Dempze Nancy E's holdings in Eli Lilly and Company were worth $2,152,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Precedent Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after buying an additional 39 shares in the last quarter. Capital Advisors Inc. OK lifted its position in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $54,000. Duquesne Family Office LLC lifted its position in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after buying an additional 32,640 shares in the last quarter. Finally, Corient IA LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $570,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on LLY shares. Daiwa Capital Markets cut Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. Guggenheim boosted their price target on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a report on Wednesday. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Finally, Morgan Stanley lowered their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus target price of $943.00.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $845.55 on Thursday. The stock's fifty day moving average is $738.69 and its 200 day moving average is $766.57. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The firm has a market capitalization of $800.28 billion, a PE ratio of 55.26, a PEG ratio of 1.18 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jamere Jackson purchased 200 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. Corporate insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.